Influence of target gene mutations on survival, stage and histology in sporadic microsatellite unstable colon cancers

被引:38
作者
Barbara, JT
Smith, EJ
Doctolero, RT
Gervaz, P
Alonso, JC
Miyai, K
Keku, T
Sandler, RS
Carethers, JM
机构
[1] VA San Diego Healthcare Syst, GI Sect, La Jolla, CA 92161 USA
[2] Vet Med Res Fdn, San Diego, CA USA
[3] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[4] Univ Hosp Geneva, Dept Surg, Geneva, Switzerland
[5] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
[6] Univ N Carolina, Dept Pathol, Chapel Hill, NC USA
[7] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[8] Univ Calif San Diego, Rebecca & John Moores Comprehens Canc Ctr, San Diego, CA 92103 USA
关键词
activin; DNA mismatch repair; transforming growth factor beta; BAX; microsatellite instability;
D O I
10.1002/ijc.21710
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
High-frequency microsatellite unstable (MSI-H) colon tumors develop as a consequence of mutations at repetitive sequences in target genes. TGFBR2 and ACVR2, encoding TGF beta superfamily receptors, and the proapoptotic gene BAX are frequent targets for frameshift mutation. We analyzed the effect of these mutations on survival and histology in 2 separate cohorts. Forty-eight MSI-H Dukes B2 colon tumors from a cohort of 172 patients had mutations in TGFBR2, BAX and ACVR2 correlated with patient survival. Further, 54 population-based MSI-H colon cancers or all stages from a cohort of 503 patients had mutations correlated with tumor stage, grade and size. Of 44 amplifiable MSI-H Dukes B2 tumors, 70% harbored TGFBR2, 63% BAX and only 4.5% ACVR2 mutations. While mutation alone did not influence survival, concomitant mutation of TGFBR2 and BAX was associated with an improved prognosis in Dukes B2 patients (p = 0.05). ACVR2 mutations were more frequent in the second, population-based cohort (stage 11: 32.5%, p < 0.05). While no target gene mutation correlated with stage in this cohort, poor histological grade and large tumor volume were associated with mutant ACVR2, but not TGFBR2 or BAX mutations, and likely accounts for the lower prevalence of ACVR2 mutations in the first, well-differentiated Dukes B2 cohort. Because target gene mutations did not correlate with stage, they likely occur early in the pathogenesis or MSI-H cancers. Mutations in TGFBR2 and BAX may improve survival in MSI-H Dukes B2 patients, and mutations of ACVR2 may augment histological changes consistent with poor tumor grade that is characteristic of MSI-H colon cancers, and increase tumor size. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:2509 / 2513
页数:5
相关论文
共 24 条
  • [1] Boland CR, 1998, CANCER RES, V58, P5248
  • [2] Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer
    Carethers, JM
    Smith, EJ
    Behling, CA
    Nguyen, L
    Tajima, A
    Doctolero, RT
    Cabrera, BL
    Goel, M
    Arnold, CA
    Miyai, K
    Boland, CR
    [J]. GASTROENTEROLOGY, 2004, 126 (02) : 394 - 401
  • [3] Prognostic significance of allelic loss at chromosome 18q21 for stage II colorectal cancer
    Carethers, JM
    Hawn, MT
    Greenson, JK
    Hitchcock, CL
    Boland, CR
    [J]. GASTROENTEROLOGY, 1998, 114 (06) : 1188 - 1195
  • [4] CARETHERS JM, 2003, TXB GASTROENTEROLOGY, P557
  • [5] Choi SW, 2002, CLIN CANCER RES, V8, P2311
  • [6] TGF-β signaling in tumor suppression and cancer progression
    Derynck, R
    Akhurst, RJ
    Balmain, A
    [J]. NATURE GENETICS, 2001, 29 (02) : 117 - 129
  • [7] Comparison of microsatellite instability and chromosomal instability in predicting survival of patients with T3N0 colorectal cancer
    Gervaz, P
    Cerottini, JP
    Bouzourene, H
    Hahnloser, D
    Doan, CL
    Benhattar, J
    Chaubert, P
    Secic, M
    Gillet, M
    Carethers, JM
    [J]. SURGERY, 2002, 131 (02) : 190 - 197
  • [8] Grady WM, 1998, CANCER RES, V58, P3101
  • [9] Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
    Gryfe, R
    Kim, H
    Hsieh, ETK
    Aronson, MD
    Holowaty, EJ
    Bull, SB
    Redston, M
    Gallinger, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (02) : 69 - 77
  • [10] HAGGITT R C, 1985, Gastroenterology, V89, P328